Asacol Leadership

Cost and Coverage

Asacol Helps Deliver an Affordable Treatment Option for Many of Your Ulcerative Colitis Patients
Medication cost may be a concern for you and your ulcerative colitis patients

* Verispan Managed Care Formulary Drug Audit, spring 2008. The spring 2008 data represent an estimated 63% of all US HMO subscribers whose prescription benefits are controlled by formularies.

† "Preferred brand tier" means "tier 2." Estimate derived from the use of information under license from IMS Formulary Focus, August 2008. IMS expressly reserves all rights, including rights of copying, distribution and republication.

‡ SDI's Vector One®: Payer, for the 6 month period ending August 2008. Out-of-pocket costs is the portion of the prescription cost that the patient is required to pay. These data include patients who pay the entire cost of their prescription and those who receive coverage via private insurance, Medicaid, or Medicare. VA and mail order co-pays are not included. Lower out of pocket costs to patients do not necessarily reflect a cost savings to providers. Products that are subject of a price comparison are not known to have comparable efficacy and safety.

References: 1. Data on file, Procter & Gamble Pharmaceuticals, Inc.

Selected Safety Information

Asacol is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses).

In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo, respectively, were headache (35% vs 36%), abdominal pain (18% vs 14%), and eructation (16% vs 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs 50%), rhinitis (42% vs 36%) , and diarrhea (35% vs 50%).

Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol.

Please see accompanying full prescribing information by clicking the link above.


This information was printed from Asacol.com.
Visit Asacol.com to get more information on Ulcerative Colitis.
Asacol is a registered trademark of Medeva Pharma Suisse AG, used under license by Procter & Gamble Pharmaceuticals, Inc.

Privacy BBB OnLine